[go: up one dir, main page]

DE60118975D1 - Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation - Google Patents

Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation

Info

Publication number
DE60118975D1
DE60118975D1 DE60118975T DE60118975T DE60118975D1 DE 60118975 D1 DE60118975 D1 DE 60118975D1 DE 60118975 T DE60118975 T DE 60118975T DE 60118975 T DE60118975 T DE 60118975T DE 60118975 D1 DE60118975 D1 DE 60118975D1
Authority
DE
Germany
Prior art keywords
inhibitors
preparation
cell proliferation
tetrahydropyridine derivatives
tetrahydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60118975T
Other languages
English (en)
Other versions
DE60118975T2 (de
Inventor
Guy Georges
Adelbert Grossmann
Olaf Mundigl
Der Saal Wolfgang Von
Tim Sattelkau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Original Assignee
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOFFMANN LA ROCHE, F Hoffmann La Roche AG filed Critical HOFFMANN LA ROCHE
Application granted granted Critical
Publication of DE60118975D1 publication Critical patent/DE60118975D1/de
Publication of DE60118975T2 publication Critical patent/DE60118975T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE60118975T 2000-12-23 2001-12-21 Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation Expired - Fee Related DE60118975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128487 2000-12-23
EP00128487 2000-12-23
PCT/EP2001/015390 WO2002051842A1 (en) 2000-12-23 2001-12-21 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors

Publications (2)

Publication Number Publication Date
DE60118975D1 true DE60118975D1 (de) 2006-05-24
DE60118975T2 DE60118975T2 (de) 2006-12-21

Family

ID=8170814

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118975T Expired - Fee Related DE60118975T2 (de) 2000-12-23 2001-12-21 Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation

Country Status (27)

Country Link
US (1) US6800638B2 (de)
EP (1) EP1353921B1 (de)
JP (1) JP2004516325A (de)
KR (1) KR100836545B1 (de)
CN (1) CN1213046C (de)
AR (1) AR035513A1 (de)
AT (1) ATE323700T1 (de)
AU (1) AU2002226397B2 (de)
BG (1) BG107935A (de)
BR (1) BR0116402A (de)
CA (1) CA2431471A1 (de)
CZ (1) CZ20031940A3 (de)
DE (1) DE60118975T2 (de)
EC (1) ECSP034664A (de)
ES (1) ES2261519T3 (de)
HU (1) HUP0400554A2 (de)
IL (1) IL156131A0 (de)
MA (1) MA26976A1 (de)
MX (1) MXPA03005713A (de)
NO (1) NO20032830L (de)
NZ (1) NZ526189A (de)
PL (1) PL365531A1 (de)
RU (1) RU2276140C2 (de)
SK (1) SK9122003A3 (de)
WO (1) WO2002051842A1 (de)
YU (1) YU48803A (de)
ZA (1) ZA200304264B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20040087657A1 (en) 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
WO2003083323A1 (en) 2002-04-01 2003-10-09 Ranko Rakanovic Rubber elastic element
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2003900608A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
WO2004082638A2 (en) 2003-03-17 2004-09-30 Syrrx, Inc. Histone deacetylase inhibitors
US20060235012A1 (en) * 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
CN1905881A (zh) * 2003-11-26 2007-01-31 阿托恩药品公司 二胺和亚氨二醋酸异羟肟酸衍生物
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1851219A1 (de) 2005-02-14 2007-11-07 Miikana Therapeutics, Inc. Fusionierte heterocyclische verbindungen als histondeacetylase-hemmer
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
KR20080032188A (ko) * 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2768466C (en) * 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
CN102153549B (zh) * 2010-12-14 2012-11-14 华东理工大学 γ咔啉化合物、制备方法和用途
PT2991982T (pt) 2013-04-29 2018-11-28 Chong Kun Dang Pharmaceutical Corp Novos compostos para inibidores seletivos de histonadesacetilase e composição farmacêutica que os compreende
EP3470536A1 (de) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren zum wirkstoffscreening auf genexpressionsrauschen und verwendungen davon
CN108084178B (zh) * 2018-01-04 2020-09-01 济南大学 一类含有四氢-β-咔碄结构的异羟肟酸类化合物的用途
CN108558653A (zh) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 赛乐西帕中间体及赛乐西帕的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002119A1 (en) * 1988-08-18 1990-03-08 Banyu Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO1998007421A1 (fr) * 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Composition medicinale
WO1998015525A1 (fr) 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Acides hydroxamiques
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AU3312100A (en) * 1999-03-22 2000-10-09 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives

Also Published As

Publication number Publication date
RU2276140C2 (ru) 2006-05-10
YU48803A (sh) 2006-05-25
BR0116402A (pt) 2003-11-11
IL156131A0 (en) 2003-12-23
BG107935A (bg) 2004-08-31
RU2003122190A (ru) 2005-02-27
AU2002226397B2 (en) 2006-10-05
ATE323700T1 (de) 2006-05-15
ECSP034664A (es) 2003-07-25
MXPA03005713A (es) 2003-10-06
US20040053960A1 (en) 2004-03-18
KR100836545B1 (ko) 2008-06-10
SK9122003A3 (en) 2004-02-03
US6800638B2 (en) 2004-10-05
WO2002051842A1 (en) 2002-07-04
NO20032830D0 (no) 2003-06-20
HUP0400554A2 (hu) 2004-06-28
ZA200304264B (en) 2004-08-30
CA2431471A1 (en) 2002-07-04
EP1353921A1 (de) 2003-10-22
PL365531A1 (en) 2005-01-10
NO20032830L (no) 2003-08-04
KR20030063424A (ko) 2003-07-28
EP1353921B1 (de) 2006-04-19
DE60118975T2 (de) 2006-12-21
JP2004516325A (ja) 2004-06-03
CZ20031940A3 (cs) 2003-10-15
MA26976A1 (fr) 2004-12-20
CN1483033A (zh) 2004-03-17
AR035513A1 (es) 2004-06-02
ES2261519T3 (es) 2006-11-16
CN1213046C (zh) 2005-08-03
NZ526189A (en) 2004-10-29

Similar Documents

Publication Publication Date Title
DE60118975D1 (de) Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE306480T1 (de) Trizyclische alkylhydroxamate, ihre herstellung und ihre verwendung als inhibitoren der zellproliferation
DE69833223D1 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
ATE461171T1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60107859D1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE60303440D1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE60127434D1 (de) Benzoxazinonderivative, deren herstellung und verwendung
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60005300D1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
ATE277023T1 (de) Indanderivate und ihre verwendung als zelladhäsionsinihibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee